Rebirth of the God-level Xueba

Give Frank three hundred pig brains, he never thought that Yang Rui would go to develop a new medicine.

After giving Frankie six hundred pig brains, Frankie couldn't think of it. Yang Rui said that when he developed a new drug, he actually produced an active substance.

Of course, active substances can be regarded as medicines. The process of developing new drugs is extremely cumbersome. If the work in the laboratory is allocated based on the workload, it may be less than one-half of the total work, and what Yang Rui has done so far, It's far away from one-third of the work in the laboratory.

Despite this, Frankie has not heard anything similar from other companies.

Arnold, who was seduced by him, has not heard anything similar.

In fact, compared to Frankie’s habit of shocking, Comrade Arnold faced the shock as an entry-level player. After entering the door of Huarui Lab, Arnold could not help but communicate with Frankie in a low voice: "It's only a few days' time?" Haven't you heard that he is doing this work? "

"Of course not. He was still working on the catalyst for Coenzyme Q10 a few days ago. Didn't he write a book in the past two months? It sells very well, and it is a professional bestseller." Frankie is indeed in the long run. Pay attention to Yang Rui. If China hadn't had the developed media and information industry in Europe and America, Frankie would have investigated Yang Rui in full.

Arnold was the person in charge of discussing the catalyst contract with Yang Rui two months ago. During his stay in Beijing, he was basically negotiating terms with Japanese and Norwegian companies.

In other words, several multinational companies are dragging their feet. They want to see the development of the situation and also want to lower Yang Rui's offer.

After all, no matter how high the profit of pharmaceuticals is, there is no reason to give 5% of the dry shares to Yang Rui in vain, and it is a dividend of global sales. Although Coenzyme Q10 is far from a blockbuster drug, even a quasi blockbuster is counted, it can be said that it is a medium-sized product with annual sales of more than 100 million yuan per company. Besides, what if it becomes a blockbuster? ?

You can't give out 50 million US dollars to Yang Rui every year. Such an agreement makes the British feel painful when they think about it.

Now, with the sales of Coenzyme Q10, the 2% income dividend is quite a lot.

Medicines are originally highly profitable products. The only high-priced raw material used in the semi-synthetic Coenzyme Q10 is refined solanesol. Under the stable market conditions, Zeneca can usually get more than 30% of profits and 2% of income dividends. This is equivalent to a 0.6% enjoyment dividend. Calculated based on the current annual sales of Coenzyme Q10 of more than 100 million US dollars, it is equivalent to a stable income of 600,000 US dollars per year, which is quite a lot and there is still room for growth.

This is also an excellent condition for biologists. Even a well-known professor in the United States, if he signs a contract, he can get 600,000 U.S. dollars in droughts and floods, and he will be happy.

Unfortunately, Yang Rui was not satisfied.

Arnold and his colleagues from other countries can only spend tacit understanding.

However, this is also a catalyst formula for Coenzyme Q10. If it is replaced with a big thing such as interferon, there will be no tacit understanding between the various companies, and they will be mad.

The price that large pharmaceutical companies are willing to pay in order to obtain a drug is unimaginable for ordinary people. For example, in order to obtain Lipitor, Pfizer finally acquired its development company Lambert for 82.4 billion U.S. dollars. While the latter’s shareholders made a profit, Pfizer also obtained 130 billion U.S. dollars in total sales from Lipitor. Its peak annual sales are 13 billion U.S. dollars, more than government taxes in many countries.

However, a catalyst that can increase the production of a drug is not a monopolized drug after all.

Arnold also put aside the catalyst matter for the time being, looked at Yang Rui's experimental records, and asked: "What kind of cooperation do you want?"

"This is our first time to develop a drug, so we need any cooperation." Yang Rui shrugged and said: "It's mainly information. If you want, I can pay a consultation fee."

"Consultation fee? How much?"

"Ten thousand dollars, reimbursement of air tickets and hotels."

Arnold laughed blankly: "Ten thousand dollars is not enough to hire an investigator."

"I know." Yang Rui smiled.

Arnold's face changed: "Do you want Zelecom to work for nothing?"

"It's not a bad thing to send two people in to keep up with our progress, right."

"That's impossible." Arnold grinned. He wanted to say that it was almost the same if you gave the Coenzyme Q10 catalyst formula to Zeleca, but this time is not suitable for mentioning it, and Arnold can bear it.

Yang Rui shrugged and said, "Then don't cooperate. I invite you to be observers. If you want to say it, just say it, even if you don't want to say it, it's in your favor, right."

"No need to sign a contract?" Arnold moved in his heart, and it did no harm to unilaterally understand the situation.

Yang Rui shook his head: "At least sign a confidential contract."

"After signing the contract, what else are we observing? Observers who can't report..."

"You only need to report the results, and you don't need to say anything about the process." Deferiprone, which has just entered the synthesis stage, will not reveal much unless it is viewed by a specialized pharmacologist or photographed.

Because of Yang Rui's relationship, Arnold was indeed very curious and couldn't help but hesitate.

"Well, you can be an observer for one day, and let's take a look." Yang Rui then asked the company lawyer who was waiting in the laboratory to come over and sign the non-disclosure agreement for Arnold.

Arnold refused, however, read the agreement carefully and signed the name.

"Old Wei, show it to the British gentlemen." Yang Rui sent white coats to the two of them, then led them into the laboratory and introduced deferiprone.

It is impossible for Yang Rui to make a normal price to Zeleca, because he cannot afford it. The medical industry is an industry with a sound industry chain to a perverted state. Every job has a price, and it is all too expensive.

For example, the most annoying clinical trials. Many people think that clinical trials are drug research conducted by the United Hospital of the pharmaceutical company or independently. However, in fact, there have been clinical trial companies in Europe and the United States for a long time, and they provide special services to various pharmaceutical companies. The clinical trial service has annual sales of over 1 billion.

As for professional consulting companies, they usually fool people, but the fees are ridiculously expensive. The million-dollar price is just the beginning.

Nowadays, pharmaceutical companies often spend tens of millions of dollars or even hundreds of millions of dollars for pre-clinical research, half of which is spent outside the laboratory, and Yang Rui cannot afford the money.

His income mainly comes from the dividends of Zelecom. His expenditure is mainly used for legal fees. The former can be slightly more than the latter, which is enough for Yang Rui to carry out some domestic experiments that are difficult to carry out, such as the synthesis of deferiprone, but after the synthesis , No part of the cost of money can be borne by Yang Rui, let alone the ability to outsource it. It is still outsourced to Zelecom.

In fact, many domestic laboratories in later generations did outsourced work from abroad, such as animal experiments, and determination of active ingredients, which were complicated and quite profitable, but in essence, they were similar in form to Foxconn. It is the profit squeezed out by reducing costs, and the reduced costs are usually scientific researchers, or students of tutors, or young masters and doctors who have just graduated.

In the long pharmaceutical industry chain, the higher the upper level, the higher the capital required, the greater the risk and the greater the profit.

Domestic companies and laboratories are weak and cannot do original drugs without outsourcing.

Even the research and development of original drugs in the 1980s was not something that Chinese laboratories could undertake.

In this regard, Yang Rui is looking for Zelican.

Asking for someone is not a comfortable thing, but you are not as skilled as a person, so you have to bow your head when it is time to bow.

Making medicine is not making art. Those who make art can advocate strengths, pretend to be wronged, can be indignant, can be angry, and can naturally be dismissed.

However, if you are not as skilled as people in making medicine, you are wasting your time and energy, wasting your accumulation and the trust of people around you.

These time, energy, accumulation and trust are often measured in ten years.

The ten years of wasting the essence of one or more researchers just to not bow their heads once. Only bureaucratic artists and beasts can do this kind of thing.

Yang Rui is not one of them.

As a novice in the pharmaceutical field, Yang Rui has little experience. Unlike writing a paper or a monograph, Yang Rui's contact with pharmaceutical factories is limited to the laboratory and production.

How to develop a drug is basically out of the direction of his education.

In China in 1984, no one understood this.

Domestic pharmaceutical companies may know how to pass the domestic drug review, but to pass the review by the drug regulatory agencies of the United States, the United Kingdom, and France, which are large drug-consuming countries, Yang Rui must seek help from Zelecom.

This is not only for the safety of the drug itself, but also for the purpose of low-cost control of thalassemia by deferiprone~www.NovelMTL.com~ The synthesis of an active substance of deferiprone is only the first step in the long march. Next, Yang Rui also needs to synthesize more deferiprone active substances in order to find the most appropriate deferiprone molecule. The same core molecule has different side chains, and the result may be completely different drug properties, and even more toxic. .

In order to complete the remaining part, the cost may be millions of dollars, tens of millions of dollars, or even hundreds of millions of dollars.

Regardless of whether Yang Rui can afford such expenses, he has no reason to do so.

The responsibility of pharmaceutical companies is to manufacture drugs, not charity, let alone charity. Deferiprone must be able to obtain sales exceeding the cost in order to continue the research and development and production lines, and Huarui can continue to develop.

To do this, foreign patients must share the cost.

"Lao Huang, you follow Arnold and Mr. Frank and show him our results. Old Wei, let's continue." Yang Rui rubbed his hands and said in English directly: "The fifth synthesis experiment of deferiprone, start. "

……Mobile phone users please visit